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Abstract 
Despite Medicare approving the use of positron emission tomography/computed tomography 
(PET/CT) in staging primary breast cancer, little evidence is available to support the use of 
18F-FDG-PET/CT for the detection of distant metastases in the initial staging of breast cancer. 
In this review of the literature listed in MEDLINE, we examine whether 
18F-FDG-PET/CT may 
play a role in the initial staging of breast cancer. We discuss studies comparing PET/CT with 
conventional imaging for diagnosing distant metastases and axillary and extra-axillary lymph 
node metastases.  
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Introduction 
Despite Medicare approving the use of positron 
emission tomography/computed tomography 
(PET/CT) in staging primary breast cancer, little evi-
dence is available to support the use of 
18F-FDG-PET/CT for the detection of distant metas-
tases in the initial staging of breast cancer. The Na-
tional Comprehensive Cancer Network recommends 
the following types of imaging for staging locally 
advanced breast cancer at the time of clinical diagno-
sis: bilateral mammography, breast ultrasonography 
as necessary, and chest imaging if patients had no 
symptoms or other abnormal staging studies, and 
breast magnetic resonance imaging (MRI), skeletal 
scintigraphy (SS), and abdominal and/or pelvic 
computed tomography (CT), ultrasonography, or MRI 
if patients had symptoms or other abnormal staging 
studies.1 Breast cancer patients with large tumors 
(stage T3 or greater) have an 8.3% to 15.1% risk of 
distant metastases.2-4 Because locally advanced breast 
cancer has a very high rate of relapse,5 it is possible 
that the conventional imaging modalities noted above 
may fail to detect a substantial number of metastases.6 
In this review, we examine whether 18F-FDG-PET/CT 
may play a role in the initial staging of breast cancer.  
Detecting Distant Metastases 
Many practicing investigators speculate that 
PET/CT might be more accurate than conventional 
imaging techniques for detecting distant metastases; 
Table 1 summarizes studies that have addressed this 
issue. Fuster et al., in a study of 60 primary breast 
cancer patients with large tumors, reported that 5 of 
the 8 cases of distant metastatic lesions were unsus-
pected before PET/CT was performed.7 Carkaci et al. 
reported that among 41 patients with inflammatory 
breast cancer, 7 of the 20 cases of distant metastases 
were unsuspected before PET/CT examination.8 Al-
berini et al. reported that among 62 patients with in-
flammatory breast cancer, 6 of 18 cases of distant me-
tastases were unsuspected before PET/CT was per-Journal of Cancer 2010, 1 
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formed.9 Heusner et al. reported that among 40 pa-
tients with breast cancer, 3 of 10 cases of distant me-
tastases were unsuspected before PET/CT was per-
formed.10 Groheux et al. reported that among 39 pa-
tients with clinical stage II and III breast cancer, all 4 
cases of distant metastases were unsuspected before 
PET/CT was performed.11 On the basis of their re-
sults, both Carkaci et al. and Alberini et al. recom-
mended the use of PET/CT in the initial staging of 
inflammatory breast cancer.8,9  
In summary, although PET/CT has an estimated 
specificity and sensitivity of 95% and 99%, not enough 
data are available to recommend the routine use of 
PET/CT in breast cancer staging because the studies 
mentioned above all had small numbers of patients. 
Further, the ability of PET/CT to detect distant me-
tastases has never been tested prospectively in a large 
group of patients. 
Detecting Axillary and Extra-Axillary Lymph 
Node Metastases 
Another possible role of PET/CT may be its use 
in detecting local lymph node metastases from breast 
cancer. PET/CT provides more detailed anatomical 
information than PET alone about axillary and ex-
tra-axillary lymph nodes.7,8 Fuster et al. reported that 
PET/CT was able to reveal previously unsuspected 
infiltration of axillary lymph nodes in 10 of 60 patients 
and infiltration of extra-axillary lymph nodes in 3 of 
60 patients.7 Carkaci et al. reported that among 41 
inflammatory breast cancer patients, PET/CT de-
tected metastases in the axillary lymph nodes of 37 
(90%), subpectoral lymph nodes of 19 (46%), suprac-
lavicular lymph nodes of 10 (24%), and internal 
mammary lymph nodes of 9 (22%).8 In the same 
study, 6 false-negative findings did not show hyper-
metabolism on PET/CT but showed malignancy on 
sonography-guided fine-needle aspiration biopsy. 
Ueda et al. reported that the diagnostic sensitivity and 
specificity of 18F-FDG-PET/CT were nearly equal to 
those of ultrasonography, 58% and 95%, respectively, 
compared with 54% and 99% in ultrasonography.12 
Conclusion 
Although the studies listed above reported some 
false-positive findings in both the lymph nodes and 
distant sites,7,8 PET/CT resulted in fewer 
false-positive findings than did PET alone.7,8 Howev-
er, not every distant metastatic site detected by 
PET/CT was confirmed by histopathological analysis 
in these studies. Diagnostic biopsy of the metastatic 
site is the gold standard for diagnosing metastatic 
lesions, and if PET/CT reveals suspected distant me-
tastases, a biopsy must be performed to confirm those 
findings. 
In summary, the use of PET/CT in the initial 
staging of primary breast cancer is not yet well de-
fined and not recommended at present because there 
is limited evidence to support its use. However, be-
cause studies have shown that PET/CT may enable 
accurate detection of local lymph node metastases and 
distant metastases, PET/CT offers another option for 
use in primary breast cancer staging. For cases in 
which conventional imaging techniques (i.e. ultraso-
nography, CT, MRI, SS) do not provide adequate in-
formation, PET/CT could be used to obtain more de-
tailed anatomical information. 
 
 
 
Table 1 Summary of studies assessing distant metastasis detected by conventional imaging with PET/CT in patients with 
primary breast cancer. 
First author  Type of study  Patient population  No. patients  Patients with distant metastases 
detected by conventional imaging 
No. (%) 
Patients with distant metas-
tases detected by PET/CT  
No. (%)  
Fuster D7  Prospective  Primary tumor >3 cm  60  3 (5)  8 (13) 
Carkaci S8 Retrospective  Primary  IBC  41  13 (32)   20 (49) 
Alberini J9 Prospective  Primary  IBC  62  12 (19)  18 (29) 
Heusner T10 Retrospective  Suspected  breast  cancer  40  7 (18)  10 (25) 
Groheux D11 Retrospective  Stage II and III   39  0  4 (10) 
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